Fallypride
Star0
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Fallypride
- DrugBank Accession Number
- DB15167
- Background
Fallypride is under investigation in clinical trial NCT02310360 (Striatal and Extra-striatal Dopamine Release in Response to Food in Healthy Humans).
- Type
- Small Molecule
- Groups
- Investigational
- Structure
- Weight
- Average: 364.461
Monoisotopic: 364.216220965 - Chemical Formula
- C20H29FN2O3
- Synonyms
- Not Available
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareApomorphine The therapeutic efficacy of Apomorphine can be decreased when used in combination with Fallypride. Aripiprazole The therapeutic efficacy of Aripiprazole can be decreased when used in combination with Fallypride. Benzatropine The risk or severity of adverse effects can be increased when Fallypride is combined with Benzatropine. Brexpiprazole The therapeutic efficacy of Brexpiprazole can be decreased when used in combination with Fallypride. Bromocriptine The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Fallypride. - Food Interactions
- Not Available
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- G9FWZ369GX
- CAS number
- 166173-78-0
- InChI Key
- OABRYNHZQBZDMG-INIZCTEOSA-N
- InChI
- InChI=1S/C20H29FN2O3/c1-4-10-23-11-6-8-16(23)14-22-20(24)17-12-15(7-5-9-21)13-18(25-2)19(17)26-3/h4,12-13,16H,1,5-11,14H2,2-3H3,(H,22,24)/t16-/m0/s1
- IUPAC Name
- 5-(3-fluoropropyl)-2,3-dimethoxy-N-{[(2S)-1-(prop-2-en-1-yl)pyrrolidin-2-yl]methyl}benzamide
- SMILES
- COC1=C(OC)C(=CC(CCCF)=C1)C(=O)NC[C@@H]1CCCN1CC=C
References
- General References
- Not Available
- External Links
- ChemSpider
- 8197265
- BindingDB
- 50220541
- ChEMBL
- CHEMBL392158
- ZINC
- ZINC000006483622
- Wikipedia
- Fallypride
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 3 Recruiting Treatment Opioid Use Disorder (OUD) / Opioids Use / Withdrawal Symptoms 1 2 Completed Treatment Healthy Volunteers (HV) 1 1 Completed Basic Science Obesity, Morbid 1 0 Completed Basic Science Healthy Volunteers (HV) / Obesity / Overweight 1 Not Available Completed Not Available Type 1 Diabetes Mellitus 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.0419 mg/mL ALOGPS logP 2.76 ALOGPS logP 2.8 Chemaxon logS -3.9 ALOGPS pKa (Strongest Acidic) 13.84 Chemaxon pKa (Strongest Basic) 7.93 Chemaxon Physiological Charge 1 Chemaxon Hydrogen Acceptor Count 4 Chemaxon Hydrogen Donor Count 1 Chemaxon Polar Surface Area 50.8 Å2 Chemaxon Rotatable Bond Count 10 Chemaxon Refractivity 101.83 m3·mol-1 Chemaxon Polarizability 40.09 Å3 Chemaxon Number of Rings 2 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS splash10-014i-0009000000-d4cd02dba06bd33485f7 Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS splash10-0j4i-2009000000-ccff4b97f56c17b4f8b5 Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS splash10-016r-1319000000-17e283e172b736667c95 Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS splash10-014i-7129000000-86aef431d7893bc595a2 Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS splash10-090c-3169000000-81251810bd2ef119d36c Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS splash10-001j-9342000000-2da4e785855b91130811 Predicted 1H NMR Spectrum 1D NMR Not Applicable Predicted 13C NMR Spectrum 1D NMR Not Applicable - Chromatographic Properties
Collision Cross Sections (CCS)
Not Available
Drug created at May 20, 2019 14:55 / Updated at June 12, 2020 16:53